Zoll Medical Corp. announced on 13 September plans to acquire Itamar Medical Ltd. for a total value of $538m, or $1.09 per ordinary share, which will add Itamar’s home-based testing for sleep apnea to Zoll’s cardiopulmonary product offerings.
SVB Leerink Research analyst Richard Newitter wrote in his flash report that the deal “looks to us like a good...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?